May 2 |
Aurinia Pharma GAAP EPS of -$0.07 beats by $0.07, revenue of $50.3M beats by $3.23M
|
May 2 |
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results
|
May 1 |
Aurinia Pharma Q1 2024 Earnings Preview
|
May 1 |
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month
|
Apr 30 |
Aurinia: Updated Lupkynis Label Should Keep Sales Growth Momentum Going
|
Apr 30 |
Aurinia gains on Lupkynis label update
|
Apr 30 |
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
|
Apr 18 |
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
|
Apr 16 |
UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
Apr 15 |
Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024
|